Tara L. Kieffer
Vertex Pharmaceuticals
74 Papers
947 Citations
Tara L. Kieffer is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Telaprevir & Hepatitis C virus. The author has an hindex of 23, co-authored 74 publications.
Chat about Author
Papers
Patent
Methods for amplifying hepatitis c virus nucleic acids
Kwong Ann Dak-Yee,James Daniel Frantz,Douglas J. Bartels,Chao Lin,Benjamin Shames,Sheila Seepersaud,Judith A. Lippke,Tara L. Kieffer,Yi Zhou,Eileen Z. Zhang,James C. Sullivan +10 more
- 21 Jan 2010
TL;DR: In this paper, a method of amplifying an HCV nucleic acid in an infected sample comprises amplifying a segment of a DNA template that is complementary to a genome of HCV RNA from the sample by a two-stage PCR.
16
VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.
Adrian M. Di Bisceglie,Mark S. Sulkowski,E.J. Gane,Ira M. Jacobson,David R. Nelson,C DeSouza,Katia Alves,Katia Alves,Shelley George,Tara L. Kieffer,Eileen Z. Zhang,Robert S. Kauffman,Mohammed Asmal,Margaret James Koziel,Margaret James Koziel +14 more
TL;DR: Telaprevir and VX-222, alone or with ribavirin without or with peginterferon, were generally well tolerated, with improved tolerability without peginerferon.
15
Patent
Hepatitis C virus variants
Chao Lin,Tara L. Kieffer,Christoph Sarrazin,Ann D. Kwong +3 more
- 13 Nov 2006
TL;DR: The present invention relates to HCV variants, particularly variants that are resistant to a protease inhibitors such as VX-950 as mentioned in this paper, and methods of isolating, identifying, and characterizing multiple viral variants from a patient.
14
Futility Rules for Telaprevir Combination Treatment for Patients With Hepatitis C Virus Infection
Nathalie Adda,Doug J. Bartels,Linda Gritz,Tara L. Kieffer,Frank Tomaka,Leif Bengtsson,Don Luo,Ira M. Jacobson,Robert S. Kauffman,Gaston Picchio +9 more
TL;DR: Retrospective analyses of data from phase 3 trials and validated the current futility rule that all therapy should be stopped for treatment-naive and treatment-experienced patients if hepatitis C virus RNA levels are greater than 1000 IU/mL at weeks 4 or 12, or if hepatitisC virus RNA is detectable at week 24.
12
Patent
Analysis of hcv genotypes
Douglas J. Bartels,Kwong Ann Dak-Yee,Tara L. Kieffer +2 more
- 28 Aug 2009
TL;DR: A method for predicting response of a patient infected with HCV-Ia to interferon treatment was proposed in this article, which is based on predicting the response of the patient to inter-feron.
12